Patricia Rios-Chavez

Prof. Patricia Rios-Chavez

Universidad Michoacana de San Nicolás de Hidalgo

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAsdrubal Aguilera-Méndez
Asdrubal Aguilera-Méndez
IFIan Axel Figueroa Fierros
Ian Axel Figueroa Fierros
XRXóchilt Ruiz-Pérez
Xóchilt Ruiz-Pérez
DGDaniel Godínez-Hernández
Daniel Godínez-Hernández
ASAlfredo Saavedra-Molina
Alfredo Saavedra-Molina
ZSZoraya Palomera Sanchez
Zoraya Palomera Sanchez
Numerous studies indicate that intrauterine growth restriction (IUGR) can predispose individuals to metabolic syndrome (MetS) in adulthood. Several reports have demonstrated that pharmacological concentrations of biotin have therapeutic effects on MetS. The present study investigated the beneficial effects of prenatal biotin supplementation in a rat model of intrauterine caloric restriction to prevent cardiometabolic risk in adult female offspring fed fructose after weaning. Female rats were exposed to a control (C) diet or global caloric restriction (20%) (GCR), with biotin (GCRB) supplementation (2 mg/kg) during pregnancy. Female offspring were exposed to 20% fructose (F) in drinking water for 16 weeks after weaning (C, C/F, GCR/F, and GCRB/F). The study assessed various metabolic parameters including Lee’s index, body weight, feed conversion ratio, caloric intake, glucose tolerance, insulin resistance, lipid profile, hepatic triglycerides, blood pressure, and arterial vasoconstriction. Results showed that GCR and GCRB dams had reduced weights compared to C dams. Offspring of GCRB/F and GCR/F dams had lower body weight and Lee’s index than C/F offspring. Maternal biotin supplementation in the GCRB/F group significantly mitigated the adverse effects of fructose intake, including hypertriglyceridemia, hypercholesterolemia, hepatic steatosis, glucose and insulin resistance, hypertension, and arterial hyperresponsiveness. This study concludes that prenatal biotin supplementation can protect against cardiometabolic risk in adult female offspring exposed to postnatal fructose, highlighting its potential therapeutic benefits.

26 March 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
AAAsdrubal Aguilera-Méndez
Asdrubal Aguilera-Méndez
KMKarel Aguilera Manuel
Karel Aguilera Manuel
ASAlfredo Saavedra-Molina
Alfredo Saavedra-Molina
PRPatricia Rios-Chavez
Patricia Rios-Chavez
SVSantiago Villafaña
Santiago Villafaña
MGMarcia Yvette Gauthereau-Torres
Marcia Yvette Gauthereau-Torres
Background: Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss. Despite advances in symptomatic management, effective disease-modifying therapies remain limited. Objectives: This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations. Methods: A narrative and integrative review was conducted, encompassing mechanistic studies, preclinical experimental models, and clinical trials and observational studies evaluating ALA and biotin in neurodegenerative diseases. The evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance. Results: ALA and biotin modulate key cellular pathways implicated in neurodegeneration, including mitochondrial metabolism, redox homeostasis, inflammatory signaling, and neurovascular function. Preclinical studies consistently report beneficial effects on mitochondrial efficiency, oxidative stress, and neuroinflammatory markers. In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders. Conclusions: ALA and biotin exhibit mechanistic convergence across pathways relevant to neurodegeneration and generally favorable safety profiles. Although current evidence supports their biological plausibility as adjunctive or exploratory therapeutic strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection. Well-designed clinical studies are required to define their efficacy, optimal dosing, and disease-specific applicability.

Verified
Journal Article
Open access
PDF file
LALuis Alberto Ayala-Ruiz
Luis Alberto Ayala-Ruiz
AGAram Josué García
Aram Josué García
OROliver Rafid Magaña Rodríguez
Oliver Rafid Magaña Rodríguez
ASAdrián Sánchez-Orozco
Adrián Sánchez-Orozco
MLManuel López
Manuel López
PRPatricia Rios-Chavez
Patricia Rios-Chavez
Diets high in fat and refined carbohydrates reliably mimic key features of metabolic dysfunction-associated fatty liver disease (MAFLD), including hepatic lipid accumulation, oxidative stress, and ongoing liver injury. This study evaluated the long-term, low-dose administration of Callistemon citrinus ethanolic leaf extract and its primary bioactive compounds: d-limonene, ellagic acid, gallic acid, and p-coumaric acid to prevent lipotoxicity in rats fed a high-fat–sucrose diet (HFSD). Sixty male Wistar rats were randomly divided into 10 groups: normal control group, an untreated HFSD group, and eight HFSD groups treated for 23 weeks with metformin, C. citrinus extract, the individual bioactive compounds, or a mixture of these compounds. We assessed body and organ weights, liver macroscopic features, serum markers of liver injury, oxidative stress biomarkers, histopathological changes, and hepatic fatty acid profiles. HFSD feeding induced significant body weight gain, hepatomegaly, severe tissue damage, elevated serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), glucose and triglycerides, alongside heightened hepatic oxidative stress, and altered saturated fatty acid profiles. Conversely, treatment with metformin and the natural compounds attenuated HFSD-induced liver injury to varying degrees. Improvements in histopathological severity and serum liver enzymes correlated with decreased oxidative stress biomarkers. Notably, ellagic acid, gallic acid, d-limonene, and the bioactive mixture, significantly improved hepatic fatty acid profiles, whereas p-coumaric acid exhibited more modest effects. These results demonstrate that long-term administration of low-dose treatment can successfully improve all evaluated metabolic, biochemical, and histological parameter, suggesting that modulating oxidative stress and liver lipid composition is strongly linked to the mitigation of liver injury in this experimental MAFLD model.